Jane Mounteney

1.1k total citations
27 papers, 654 citations indexed

About

Jane Mounteney is a scholar working on Epidemiology, Toxicology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jane Mounteney has authored 27 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 8 papers in Toxicology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jane Mounteney's work include Substance Abuse Treatment and Outcomes (8 papers), HIV, Drug Use, Sexual Risk (8 papers) and Forensic Toxicology and Drug Analysis (7 papers). Jane Mounteney is often cited by papers focused on Substance Abuse Treatment and Outcomes (8 papers), HIV, Drug Use, Sexual Risk (8 papers) and Forensic Toxicology and Drug Analysis (7 papers). Jane Mounteney collaborates with scholars based in Portugal, Norway and Australia. Jane Mounteney's co-authors include Paul Griffiths, Isabelle Giraudon, Gleb Denissov, Roland Simon, Julián Vicente, Siren Haugland, Roumen Sedefov, Alessandra Bò, Siri Håvås Haugland and Linda Montanari and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Addiction and European Journal of Pain.

In The Last Decade

Jane Mounteney

26 papers receiving 617 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Mounteney Portugal 15 249 249 231 145 113 27 654
Rachel Sutherland Australia 18 220 0.9× 278 1.1× 153 0.7× 159 1.1× 97 0.9× 65 805
Bryce Pardo United States 17 224 0.9× 479 1.9× 538 2.3× 95 0.7× 224 2.0× 39 961
Isabelle Giraudon Portugal 18 400 1.6× 273 1.1× 264 1.1× 202 1.4× 189 1.7× 43 998
Julián Vicente Portugal 14 164 0.7× 577 2.3× 324 1.4× 191 1.3× 137 1.2× 31 1.0k
Chris Yates Spain 17 350 1.4× 64 0.3× 106 0.5× 171 1.2× 222 2.0× 42 940
Vendula Běláčková Australia 14 90 0.4× 289 1.2× 121 0.5× 86 0.6× 171 1.5× 36 463
Andreas Kimergård United Kingdom 15 114 0.5× 136 0.5× 123 0.5× 87 0.6× 94 0.8× 30 652
Michael Gilbert United States 10 164 0.7× 314 1.3× 519 2.2× 32 0.2× 52 0.5× 21 713
Michael Evans‐Brown Portugal 13 353 1.4× 109 0.4× 107 0.5× 173 1.2× 162 1.4× 28 700
Rachael Butler New Zealand 12 131 0.5× 142 0.6× 124 0.5× 136 0.9× 67 0.6× 31 483

Countries citing papers authored by Jane Mounteney

Since Specialization
Citations

This map shows the geographic impact of Jane Mounteney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Mounteney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Mounteney more than expected).

Fields of papers citing papers by Jane Mounteney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Mounteney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Mounteney. The network helps show where Jane Mounteney may publish in the future.

Co-authorship network of co-authors of Jane Mounteney

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Mounteney. A scholar is included among the top collaborators of Jane Mounteney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Mounteney. Jane Mounteney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bretteville‐Jensen, Anne Line, Ellen J. Amundsen, & Jane Mounteney. (2022). Key Interpretation Challenges for Wastewater-Based Epidemiology of Illicit Drugs: A Norwegian Three-City Case Study. European Addiction Research. 28(6). 436–445. 3 indexed citations
2.
Montanari, Linda, Roberto Ranieri, Jane Mounteney, et al.. (2021). The impact of the COVID-19 lockdown on drug service provision in European prisons. International Journal of Prisoner Health. 17(3). 217–232. 3 indexed citations
3.
Seyler, Thomas, et al.. (2021). Is Europe facing an opioid epidemic: What does European monitoring data tell us?. European Journal of Pain. 25(5). 1072–1080. 40 indexed citations
4.
Storti, Cláudia Costa, Anne Line Bretteville‐Jensen, Paul De Grauwe, et al.. (2021). The Double Effect of COVID-19 Confinement Measures and Economic Recession on High-Risk Drug Users and Drug Services. European Addiction Research. 27(4). 239–241. 7 indexed citations
5.
Roxburgh, Amanda, Bülent Şam, Pirkko Kriikku, et al.. (2021). Trends in MDMA‐related mortality across four countries. Addiction. 116(11). 3094–3103. 16 indexed citations
6.
Griffiths, Paul, et al.. (2018). The challenge of responding to a more globally joined-up, dynamic, and innovative drug market: Reflections from the EMCDDA´s 2018 analysis of the European drug situation. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. 31(3). 231–237. 2 indexed citations
7.
Mounteney, Jane, Paul Griffiths, Alessandra Bò, et al.. (2017). Nine reasons why ecstasy is not quite what it used to be. International Journal of Drug Policy. 51. 36–41. 18 indexed citations
8.
Montanari, Linda, et al.. (2017). Cannabis Use among People Entering Drug Treatment in Europe: A Growing Phenomenon?. European Addiction Research. 23(3). 113–121. 32 indexed citations
9.
Pirona, Alessandro, Alessandra Bò, Dagmar Hedrich, et al.. (2016). New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe. International Journal of Drug Policy. 40. 84–92. 38 indexed citations
10.
Mounteney, Jane, Paul Griffiths, Andrew Cunningham, et al.. (2016). Continued signs of resilience in the European drug market: Highlights from the EMCDDA’s 2016 European drug report. Drugs Education Prevention and Policy. 23(6). 492–495. 5 indexed citations
11.
Griffiths, Paul & Jane Mounteney. (2016). Disruptive Potential of the Internet to Transform Illicit Drug Markets and Impact on Future Patterns of Drug Consumption. Clinical Pharmacology & Therapeutics. 101(2). 176–178. 10 indexed citations
12.
Mounteney, Jane, Isabelle Giraudon, Gleb Denissov, & Paul Griffiths. (2015). Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe. International Journal of Drug Policy. 26(7). 626–631. 128 indexed citations
13.
14.
Mounteney, Jane, Siri Håvås Haugland, & Arvid Skutle. (2010). Truancy, alcohol use and alcohol-related problems in secondary school pupils in Norway. Health Education Research. 25(6). 945–954. 40 indexed citations
15.
Mounteney, Jane, Craig Fry, Neil McKeganey, & Siren Haugland. (2009). Challenges of Reliability and Validity in the Identification and Monitoring of Emerging Drug Trends. Substance Use & Misuse. 45(1-2). 266–287. 22 indexed citations
16.
Mounteney, Jane, et al.. (2008). Youth, risk and rapid assessment: a new model for community social work assessment?. European Journal of Social Work. 11(3). 221–235. 3 indexed citations
17.
Mounteney, Jane & Siren Haugland. (2007). Earlier warning: A multi-indicator approach to monitoring trends in the illicit use of medicines. International Journal of Drug Policy. 20(2). 161–169. 21 indexed citations
18.
Mounteney, Jane, et al.. (2004). Providing an earlier warning of emerging drug trends: the føre var system. Drugs Education Prevention and Policy. 11(6). 449–471. 21 indexed citations
19.
20.
Mounteney, Jane, et al.. (1994). Sexually challenged: drug agencies and safer sex advice for young people. Health Education Journal. 53(4). 385–396.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Sutherland Breakdown of academic impact, for papers by Bryce Pardo Breakdown of academic impact, for papers by Isabelle Giraudon Breakdown of academic impact, for papers by Julián Vicente Breakdown of academic impact, for papers by Chris Yates Breakdown of academic impact, for papers by Vendula Běláčková Breakdown of academic impact, for papers by Andreas Kimergård Breakdown of academic impact, for papers by Michael Gilbert Breakdown of academic impact, for papers by Michael Evans‐Brown Breakdown of academic impact, for papers by Rachael Butler
Rankless by CCL
2026